PDE9A and Huntington disease: The effectiveness of PDE9A inhibition for increasing cortically-driven activity in the TG5 rat striatum supports the targeting of PDE9A or other cGMP effector proteins (e.g., PKG, CNGCs) for therapeutic intervention in HD.